Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in an oral presentation at the DDR Inhibitors Summit, being held January 27-29, 2026 in Boston (MA), USA.
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it will present preclinical data from its polymerase theta (Pol θ / POLQ) inhibitor programme in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024 in Barcelona, Spain (ENA 2024).
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential, for the treatment of solid tumours. IND-enabling activities have already commenced.
Breakpoint’s Managing Directors Daniel Speidel and Jon Hollick will attend the DDR Inhibitors Summit 2024 in Boston (30 January- 1 February 2024). At this international meeting, experts from industry and academia gather to share and discuss updates in the development of novel therapeutics targeting the DNA Damage response in cancer cells. Daniel Speidel will chair […]
Breakpoint’s Managing Director Daniel Speidel will present a company overview during JPM at Biotech Showcase in San Francisco on January 9, 2024. Hilton Union Square 2:15 pm, Franciscan C.
Breakpoint’s Managing Director Jon Hollick will present a talk entitled “Decoding DNA Damage Response (DDR) Efficacy in Tumour Models to Advance Translation into the Clinic” at the 12th Annual Tumour Models London Summit (06-07 December 2023). He will also participate in the opening plenary panel discussing “How Do You Select the Best Model for Your […]
Breakpoint’s Managing Director Jon Hollick will present a company overview at the LSX Inv€$tival Showcase in London on November 13, 2023.
Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO Investor Forum in San Francisco on October 18, 2023. 10:00am, Franciscan C.
Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO International Convention in Boston on June 7, 2023. 12:15pm, Session Room 104A.
Breakpoint’s Managing Director and Head of Research Jon Hollick will give a talk entitled “Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold” at the DDR Inhibitors Summit in Boston, 24-26 January 2023.
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
